Information Provided By: 
Fly News Breaks for September 26, 2018
ALDX
Sep 26, 2018 | 11:52 EDT
Canaccord analyst John Newman raised his price target on Aldeyra shares to $35 from $27 after the company's Phase 2b trial of topical ocular reproxalap in patients with dry eye disease achieved statistically significant improvement against vehicle for all imputation techniques, which he called a "major positive." The very rapid onset of action is differentiating, said the analyst, who expects positive Phase 3 dry eye data given the Phase 2b results. He maintains a Buy rating on Aldeyra shares.
News For ALDX From the Last 2 Days
There are no results for your query ALDX
